Orchid Pharma Limited (ORCHPHARMA) - Total Assets
Based on the latest financial reports, Orchid Pharma Limited (ORCHPHARMA) holds total assets worth Rs17.22 Billion INR (≈ $186.23 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Orchid Pharma Limited book value and equity for net asset value and shareholders' equity analysis.
Orchid Pharma Limited - Total Assets Trend (2004–2025)
This chart illustrates how Orchid Pharma Limited's total assets have evolved over time, based on quarterly financial data.
Orchid Pharma Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Orchid Pharma Limited's total assets of Rs17.22 Billion consist of 47.8% current assets and 52.2% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 1.3% |
| Accounts Receivable | Rs2.42 Billion | 14.3% |
| Inventory | Rs3.26 Billion | 19.3% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs170.14 Million | 1.0% |
| Goodwill | Rs0.00 | 0.0% |
Asset Composition Trend (2004–2025)
This chart illustrates how Orchid Pharma Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Orchid Pharma Limited.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Orchid Pharma Limited's current assets represent 47.8% of total assets in 2025, an increase from 36.8% in 2004.
- Cash Position: Cash and equivalents constituted 1.3% of total assets in 2025, up from 0.9% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 2.0% in 2004.
- Asset Diversification: The largest asset category is inventory at 19.3% of total assets.
Orchid Pharma Limited Competitors by Total Assets
Key competitors of Orchid Pharma Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.15 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Guobang Pharma Ltd
SHG:605507
|
China | CN¥10.58 Billion |
Orchid Pharma Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.35 | 2.96 | 2.91 |
| Quick Ratio | 1.90 | 1.82 | 1.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs4.95 Billion | Rs5.52 Billion | Rs3.48 Billion |
Orchid Pharma Limited - Advanced Valuation Insights
This section examines the relationship between Orchid Pharma Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.09 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 8.6% |
| Total Assets | Rs16.88 Billion |
| Market Capitalization | $343.23 Million USD |
Valuation Analysis
Below Book Valuation: The market values Orchid Pharma Limited's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Orchid Pharma Limited's assets grew by 8.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Orchid Pharma Limited (2004–2025)
The table below shows the annual total assets of Orchid Pharma Limited from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs16.88 Billion ≈ $182.54 Million |
+8.63% |
| 2024-03-31 | Rs15.54 Billion ≈ $168.05 Million |
+26.83% |
| 2023-03-31 | Rs12.25 Billion ≈ $132.50 Million |
+10.32% |
| 2022-03-31 | Rs11.11 Billion ≈ $120.10 Million |
-10.24% |
| 2021-03-31 | Rs12.37 Billion ≈ $133.80 Million |
-15.25% |
| 2020-03-31 | Rs14.60 Billion ≈ $157.88 Million |
-52.55% |
| 2019-03-31 | Rs30.77 Billion ≈ $332.77 Million |
-1.55% |
| 2018-03-31 | Rs31.25 Billion ≈ $338.00 Million |
-4.00% |
| 2017-03-31 | Rs32.56 Billion ≈ $352.08 Million |
-15.70% |
| 2016-03-31 | Rs38.62 Billion ≈ $417.67 Million |
-4.91% |
| 2015-03-31 | Rs40.61 Billion ≈ $439.22 Million |
-12.68% |
| 2013-03-31 | Rs46.51 Billion ≈ $502.99 Million |
+16.67% |
| 2012-03-31 | Rs39.86 Billion ≈ $431.11 Million |
-2.07% |
| 2011-03-31 | Rs40.71 Billion ≈ $440.21 Million |
+7.87% |
| 2010-03-31 | Rs37.74 Billion ≈ $408.10 Million |
-10.87% |
| 2009-03-31 | Rs42.34 Billion ≈ $457.89 Million |
+21.52% |
| 2008-03-31 | Rs34.84 Billion ≈ $376.81 Million |
+20.52% |
| 2007-03-31 | Rs28.91 Billion ≈ $312.65 Million |
+33.32% |
| 2006-03-31 | Rs21.69 Billion ≈ $234.52 Million |
+19.64% |
| 2005-03-31 | Rs18.12 Billion ≈ $196.01 Million |
+26.94% |
| 2004-03-31 | Rs14.28 Billion ≈ $154.41 Million |
-- |
About Orchid Pharma Limited
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, m… Read more